Henry Schein (NASDAQ:HSIC) Stock Rating Upgraded by Wall Street Zen

Henry Schein (NASDAQ:HSIC) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Monday.

A number of other analysts have also recently weighed in on the stock. Barrington Research set a $104.00 price target on shares of Henry Schein in a report on Wednesday, August 5th. Barclays reiterated an “overweight” rating and set a $100.00 price objective (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Morgan Stanley reissued an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. BTIG Research reaffirmed a “buy” rating and issued a $100.00 price target on shares of Henry Schein in a report on Wednesday, August 5th. Finally, Citigroup reaffirmed a “buy” rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Henry Schein currently has an average rating of “Hold” and an average target price of $92.27.

Henry Schein Trading Down 0.3%

Shares of NASDAQ:HSIC opened at $89.23 on Monday. Henry Schein has a 12-month low of $61.94 and a 12-month high of $92.18. The business’s fifty day simple moving average is $85.22 and its 200-day simple moving average is $79.26. The company has a market capitalization of $9.94 billion, a PE ratio of 26.01, a P/E/G ratio of 1.71 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The firm had revenue of $3.46 billion during the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the prior year, the business posted $1.10 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, equities research analysts predict that Henry Schein will post 5.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein during the 2nd quarter worth approximately $27,000. Federated Hermes Inc. purchased a new position in Henry Schein during the 4th quarter worth approximately $32,000. Los Angeles Capital Management LLC acquired a new stake in Henry Schein during the 4th quarter valued at approximately $37,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Henry Schein in the 2nd quarter valued at $42,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.